---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000072"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-09-21T23:59:59+00:00"
generated_at: "2026-06-23T08:19:14.205517+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost

## Summary
- Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.
- Allogene can elect ex-US license; if exercised, milestone payments for ALLO-501A increase by €46M aggregate.
- Allogene's right to recover 40% of development costs from Servier would cease upon exercise of ex-US option.
- Servier requested Allogene exercise option within limited timeframe; Cellectis challenges sublicense rights, adding legal risk.

## SEC filing metadata
- accession: 0001737287-22-000072
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/0001737287-22-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/allo-20220915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000072
- JSON: https://secwatch.observer/filing/0001737287-22-000072.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.